AZD8154   Click here for help

GtoPdb Ligand ID: 11204

Synonyms: AZD-8154 | Example 1 [WO2018055040A1]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD8154 is one of the chemical structures in a patent from AstraZeneca that claims dual phosphatidylinositol 3-kinase (PI3K) δ/γ inhibitors [1]. Its discovery was formally disclosed by Perry et al., in June 2021 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 149.19
Molecular weight 551.17
XLogP 3.45
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C[C@H](N1Cc2c(C1=O)c(cc(c2)c1sc(nc1C)Nc1cccc(n1)N1CCCC1=O)S(=O)(=O)C)C1CC1
Isomeric SMILES C[C@H](N1Cc2c(C1=O)c(cc(c2)c1sc(nc1C)Nc1cccc(n1)N1CCCC1=O)S(=O)(=O)C)C1CC1
InChI InChI=1S/C27H29N5O4S2/c1-15-25(37-27(28-15)30-21-6-4-7-22(29-21)31-11-5-8-23(31)33)18-12-19-14-32(16(2)17-9-10-17)26(34)24(19)20(13-18)38(3,35)36/h4,6-7,12-13,16-17H,5,8-11,14H2,1-3H3,(H,28,29,30)/t16-/m0/s1
1. Perry M, Karabelas K, Mogemark M, Bold P, Tyrchan C, Nikitidid A, Petersen J, Borjesson U. (2018)
5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma.
Patent number: WO2018055040A1. Assignee: Astrazeneca Ab. Priority date: 22/09/2016. Publication date: 29/03/2018.
2. Perry MWD, Björhall K, Bold P, Brűlls M, Börjesson U, Carlsson J, Chang HA, Chen Y, Eriksson A, Fihn BM et al.. (2021)
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.
J Med Chem, 64 (12): 8053-8075. [PMID:34080862]
3. Sadiq MW, Asimus S, Belvisi MG, Brailsford W, Fransson R, Fuhr R, Hagberg A, Hashemi M, Jellesmark Jensen T, Jonsson J et al.. (2022)
Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
Br J Clin Pharmacol, 88 (1): 260-270. [PMID:34182611]